Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.75 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | THRB | P10828 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13405878 | 0.92 | HTT (0.84) | HTTSMN1; SMN2LMNAGAA | |
| SCHEMBL10454789 | 0.87 | HTT (0.76) | HTTSMN1; SMN2LMNAGAATHRB | |
| SCHEMBL13405873 | 0.86 | SMN1; SMN2 (1.00) | HTTSMN1; SMN2LMNAGAATHRB | |
| SCHEMBL12851299 | 0.85 | HTT (0.74) | HTTSMN1; SMN2LMNAGAATSHR | |
| SCHEMBL16133686 | 0.85 | HTT (0.73) | HTTSMN1; SMN2LMNAGAATHRB | |
| SCHEMBL17481131 | 0.84 | GAA (0.81) | HTTSMN1; SMN2LMNAGAATSHR | |
| SCHEMBL13405884 | 0.83 | TSHR (0.83) | HTTSMN1; SMN2LMNAGAATHRB | |
| SCHEMBL13405897 | 0.82 | SMN1; SMN2 (0.79) | HTTSMN1; SMN2LMNAGAATSHR | |
| SCHEMBL18661208 | 0.82 | HTT (0.70) | HTTSMN1; SMN2LMNATSHRALDH1A1 | |
| SCHEMBL6304380 | 0.81 | BCHE (0.69) | HTTSMN1; SMN2LMNAGAATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776996-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9365570-B2 | Substituted 6, 5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20160024081-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. | 2016-01-28 | — | — | US | disclosed |
| US-20150246916-A1 | Substituted 6, 5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. | 2015-09-03 | — | — | US | disclosed |
| US-9045477-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20140296283-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. (US) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024081-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | CYP3A5, PAICS, CYP4B1 | HTT 906/4885SMN1; SMN2 4624/4885LMNA 2821/4885 |
| US-20150246916-A1 | Substituted 6, 5-Fused Bicyclic Heteroaryl Compounds | CYP3A5, PAICS, CYP4B1 | HTT 906/4885SMN1; SMN2 4624/4885LMNA 2821/4885 |
| US-20140296283-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | CYP3A5, PAICS, CYP4B1 | HTT 906/4885SMN1; SMN2 4624/4885LMNA 2821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.